

News Releases

All Years



Search

GO

[Advanced Search](#)

Mar 18, 2014

Portola Pharmaceuticals Appoints John H. Johnson to Board of Directors

SOUTH SAN FRANCISCO, Calif., March 18, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced the appointment of John H. Johnson to its board of directors effective March...

Feb 27, 2014

Portola Pharmaceuticals Reports Fourth Quarter and Year-End 2013 Financial Results and Provides Corporate Update

Conference Call Today at 4:30 p.m. ET

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced a corporate update and reported its financial results for the fourth quarter...

Feb 24, 2014

Portola Pharmaceuticals to Present at the Cowen and Company 34th Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that William Lis, chief executive officer, will present at the Cowen and Company 34

Feb 20, 2014

Portola Pharmaceuticals to Announce Fourth Quarter and Year End 2013 Financial Results and Host Conference Call on Thursday, February 27, 2014

SOUTH SAN FRANCISCO, Calif., Feb. 20, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) today announced that it will host a webcast and conference call to discuss the Company's...

Feb 3, 2014

Portola Pharmaceuticals Enters Into Clinical Collaboration Agreement With Bayer and Janssen for Phase 3 Studies of Andexanet Alfa*, Investigational Factor Xa Inhibitor Reversal Agent, and XARELTO(R)

Portola to Receive Upfront and Milestone Payments While Retaining Full Worldwide Rights to Andexanet Alfa

SOUTH SAN FRANCISCO, Calif., Feb. 3, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that it has entered into a second clinical collaboration agreement with Bayer...

Show 5



per

< [1](#) ... [41](#) [42](#) [43](#) [44](#) [45](#) [46](#) [47](#) ... [50](#) >

page

